Lymph node ratio predicts adjuvant chemotherapy benefit in esophageal squamous cell carcinoma.

31 Although the updated OS data presented at the 2025 ASCO annual meeting showed a favorable trend, statistical significance was not reached. 32 Moreover, another retrospective study reported that adjuvant nivolumab following neoadjuvant DCF chemotherapy could further improve both disease-free survival and OS in patients with locally advanced ESCC, with particularly pronounced benefits observed in those with ypStage III disease. 33 These studies suggest that patients who fail to achieve a complete pathological response may still benefit from intensified adjuvant therapy.

also in 957 other papers

Additionally, even patients with an LNR <4.17% showed a trend of benefit from postoperative adjuvant therapy, though not statistically significant.

also in 31,039 other papers